500mg Fulvestrant Versus Exemestane in MBC

Fudan University

Status: Completed

Conditions: Breast Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT03575260

YOUNGBC-2

Details and patient eligibility

About

500mg Fulvestrant versus Exemestane in MBC

Full description

500mg Fulvestrant versus Exemestane in Metastatic Breast Cancer (MBC) resistant to adjuvant Non-steroidal Aromatase Inhibitors in clinical practice- a multicenter retrospective study

Enrollment: 120 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Postmenopausal woman, age > 18 years old
• Diagnosed with ER/PR+，HER2- Metastatic Breast Cancer
• Adjuvant treatment of Non-steroidal Aromatase Inhibitors
• First line of Metastatic Breast Cancer is 500mg Fulvestrant or Exemestane for at least one month, starting from 2014.01.01-2017.06.01
• Available medical history

Exclusion criteria

• Incomplete medical history

Trial design

120 participants in 2 patient groups

Fulvestrant

Description:

Fulvestrant 500 mg on days 0, 14, and 28, and every 28 days thereafter

Exemestane

Description:

Exemestane 25mg per day